Lamotrigine [‘Lamictal’], one of the new generation of anticonvulsants, has been effectively used in adults with a variety of epilepsies and seizures as adjunctive therapy in refractory disease, and, more recently, as monotherapy in less severe seizures. Recently, lamotrigine has been advocated for use in children with difficult-to-treat seizures. Numerous studies exploring the efficacy of lamotrigine therapy were presented at the 23rd International Epilepsy Congress [Prague, Czech Republic; September 1999].